Investment Thesis
Tevogen Bio is in critical financial distress with negative stockholders equity of -$8.2M, zero cash reserves, and severe liquidity crisis (current ratio 0.22x). The company burns -$12.4M annually in free cash flow against near-zero revenue, creating imminent insolvency risk without immediate capital infusion.
Strengths
- Marginal net loss improvement of 2.1% YoY indicates some cost control efforts
- Biotech sector structure allows for potential value creation if clinical/commercial progress is achieved
- Basic financial reporting infrastructure maintained
Risks
- Negative stockholders equity (-$8.2M) indicates technical insolvency
- Zero cash reserves combined with -$12.4M annual free cash burn creates critical liquidity crisis
- Current ratio of 0.22x demonstrates inability to meet short-term obligations
- Negative revenue of -$195.6K suggests operational distress
- High bankruptcy risk without immediate debt restructuring or capital raise
Key Metrics to Watch
- Cash position and months of runway remaining
- Stockholders equity recovery path and balance sheet restructuring
- Revenue inflection point and transition to positive operating cash flow
- Capital raise announcements or debt restructuring actions
Financial Metrics
Revenue
-195.6K
Net Income
-26.3M
EPS (Diluted)
$-8.08
Free Cash Flow
-12.4M
Total Assets
4.4M
Cash
0.0
Profitability Ratios
Gross Margin
N/A
Operating Margin
13,363.0%
Net Margin
13,432.0%
ROE
N/A
ROA
-599.5%
FCF Margin
6,335.3%
Balance Sheet & Liquidity
Current Ratio
0.22x
Quick Ratio
0.22x
Debt/Equity
N/A
Debt/Assets
287.9%
Interest Coverage
-1,063.88x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T00:03:21.900668 |
Data as of: 2025-12-31 |
Powered by Claude AI